Lung cancer: open trials in Belgium

126 open trials have a site in Belgium. Registry data; only the trial team decides who can take part.

NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
JESSA Ziekenhuis, Hasselt · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Namur · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-11-05
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Hoffmann-La Roche
AZORG Campus Aalst-Moorselbaan, Aalst · Cliniques Universitaires St-Luc, Brussels · UZ Brussel, Brussels · Jessa Zkh (Campus Virga Jesse), Hasselt · UZ Leuven Gasthuisberg, Leuven · CHU de Liège (Sart Tilman), Liège · CHU HELORA - Hôpital de Mons - Site Kennedy, Mons · AZ Delta (Campus Rumbeke), Roeselare
Registry updated 2026-11-05
NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · Pfizer
Algemeen Ziekenhuis klina, Brasschaat · Grand Hopital de Charleroi, Charleroi · JESSA Ziekenhuis, Hasselt · A.Z. Sint-Maarten, Mechelen
Registry updated 2026-11-05
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Institut Jules Bordet, Anderlecht · Algemeen Ziekenhuis klina, Brasschaat · Grand Hopital de Charleroi, Charleroi · Ziekenhuis Oost-Limburg, Genk · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven · Vitaz, Sint-Niklaas
Registry updated 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Het Ziekenhuisnetwerk Antwerpen, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge · CHIREC, Brussels · Universitair Ziekenhuis Gent, Gent · Algemeen Ziekenhuis Groeninge, Kortrijk · UZ Leuven, Leuven · A.Z. Sint-Maarten, Mechelen · Clinique Saint Pierre, Ottignies-Louvain-la-Neuve · Werken Glorieux, Ronse · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
Antwerp University Hospital, Edegem · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-11-04
NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
CHIREC - site delta, Auderghem · Antwerp University Hospital, Edegem · UZ Leuven, Leuven · AZ Delta vzw, Roeselare
Registry updated 2026-11-04
NCT07492680
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Trial Treatment · Phase 2 · Bristol-Myers Squibb
UZ Brussel, Brussels · Cliniques universitaires Saint-Luc, Brussels · UZ Gent, Ghent
Registry updated 2026-11-04
NCT07659782
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Trial Treatment · Phase 2 · Verastem, Inc.
Universitair Ziekenhuis Gent, Gent · Centre Hospitalier Universitaire de Liège, Liège · Centre Hospitalier Regional de la Citadelle, Liège · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Namur
Registry updated 2026-11-04
2022-502959-54-00
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Trial Treatment · Phase 3 · Dizal Pharmaceutical Co. Ltd.
Grand Hopital de Charleroi, Charleroi · Antwerp University Hospital, Edegem · Universitair Ziekenhuis Gent, Gent
Registry updated 2026-11-03
NCT05856981
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Trial Treatment · Phase 1 · Sairopa B.V.
Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame, Charleroi
Registry updated 2026-11-03
NCT06303505
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Trial Treatment · Phase 1/2 · Gilead Sciences
Universitair Ziekenhuis Gent, Gent · Algemeen Ziekenhuis Groeninge, Kortrijk · UZ Leuven, Leuven · Emmaues, Mechelen · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-11-03
NCT06667076
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Ziekenhuis Oost-Limburg, Genk · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven · CHU UCL Namur - Site Godinne, Yvoir
Registry updated 2026-11-03
NCT07230691
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Research · Janssen Research & Development, LLC
UZ Brussel, Brussels · UZ Antwerpen, Edegem · JESSA Ziekenhuis, Hasselt · AZ Groeninge, Kortrijk · Chu Helora Hospital La Louviere Site Jolimont, La Louvière · CHU de Liège, Liège · Vitaz, Sint-Niklaas
Registry updated 2026-11-03
NCT07288177
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Trial Treatment · Phase 2 · Genmab
Institut Jules Bordet, Anderlecht · Universitair Ziekenhuis Antwerpen, Edegem · JESSA Ziekenhuis, Hasselt · Chu Helora, La Louvière · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-11-03
NCT07365319
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Trial Treatment · Phase 2/3 · Eikon Therapeutics
Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann, Brussels · Universitair Ziekenhuis Antwerpen, Edegem
Registry updated 2026-11-03
NCT07566052
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Trial Treatment · Phase 3 · Astellas Pharma Global Development, Inc.
Grand Hopital de Charleroi, Charleroi · Universitair Ziekenhuis Antwerpen, Edegem · AZ Sint-Lucas & Volkskliniek, Gent · Universitair Ziekenhuis Gent, Gent · Az Maria Middelares Gent, Gent · JESSA Ziekenhuis, Hasselt · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · Vitaz, Sint-Niklaas
Registry updated 2026-11-03
NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Trial Treatment · Phase 2/3 · BioNTech SE
Universitair Ziekenhuis Gent, Gent · JESSA Ziekenhuis, Hasselt · UZ Leuven, Leuven · CHU Helora, Mons · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe · Vitaz, Sint-Niklaas
Registry updated 2026-11-02
NCT06745908
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Trial Treatment · Phase 3 · ImmunityBio, Inc.
Grand Hopital de Charleroi, Charleroi · Az Maria Middelares Gent, Gent · JESSA Ziekenhuis, Hasselt · Pôle Hospitalier Jolimont, La Louvière · Centre Hospitalier Regional de la Citadelle, Liège · Centre Hospitalier Universitaire de Liège, Liège · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Namur
Registry updated 2026-11-02
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Trial Treatment · Phase 3 · Boehringer Ingelheim
Universitair Ziekenhuis Antwerpen, Edegem · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège
Registry updated 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Antwerp University Hospital, Edegem · Az Maria Middelares Gent, Gent · JESSA Ziekenhuis, Hasselt
Registry updated 2026-10-30
NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Universitair Ziekenhuis Gent, Gent · JESSA Ziekenhuis, Hasselt · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-10-30
NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · AbbVie
Algemeen Ziekenhuis klina, Brasschaat · Institut Jules Bordet, Brussels · Grand Hopital de Charleroi, Charleroi · Antwerp University Hospital, Edegem · Az Maria Middelares Gent, Gent · Universitair Ziekenhuis Gent, Gent · JESSA Ziekenhuis, Hasselt · Pôle Hospitalier Jolimont, La Louvière · CHU de Liège, Liège · CHU UCL Namur, Namur · Vitaz, Sint-Niklaas
Registry updated 2026-10-29
NCT06692738
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · AstraZeneca
CHIREC, Brussels · Grand Hopital de Charleroi, Charleroi · Algemeen Ziekenhuis Groeninge, Kortrijk · Clinique Saint Pierre, Ottignies-Louvain-la-Neuve
Registry updated 2026-10-29
NCT04886804
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Trial Treatment · Phase 1 · Boehringer Ingelheim
Institut Jules Bordet, Anderlecht
Registry updated 2026-10-28

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error